Condition
Recurrent Ependymoma
ClinicalTrials.gov condition label
Clinical trials
8 shownSelpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialNCT04320888 · 2021-05-03
ACTIVE_NOT_RECRUITINGTipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialNCT04284774 · 2020-10-13
ACTIVE_NOT_RECRUITINGIvosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)NCT04195555 · 2020-07-20
ACTIVE_NOT_RECRUITINGEnsartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)NCT03213652 · 2018-04-17
ACTIVE_NOT_RECRUITINGSamotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)NCT03213678 · 2017-11-28
COMPLETEDTazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)NCT03213665 · 2017-11-13
COMPLETEDLarotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)NCT03213704 · 2017-08-23
ACTIVE_NOT_RECRUITINGTargeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)NCT03155620 · 2017-07-31
ACTIVE_NOT_RECRUITINGCommon interventions
Computed TomographyPROCEDURE5Magnetic Resonance ImagingPROCEDURE5X-Ray ImagingPROCEDURE5Biospecimen CollectionPROCEDURE4Radionuclide ImagingPROCEDURE4Bone Marrow Aspiration and BiopsyPROCEDURE3Bone ScanPROCEDURE3Positron Emission TomographyPROCEDURE3EnsartinibDRUG2IvosidenibDRUG2Laboratory Biomarker AnalysisOTHER2Larotrectinib SulfateDRUG2Pharmacological StudyOTHER2SamotolisibDRUG2SelpercatinibDRUG2TazemetostatDRUG2TipifarnibDRUG2Biopsy ProcedurePROCEDURE1ErdafitinibDRUG1FDG-Positron Emission TomographyPROCEDURE1Mutation Carrier ScreeningPROCEDURE1OlaparibDRUG1PalbociclibDRUG1Selumetinib SulfateDRUG1UlixertinibDRUG1
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING6
COMPLETED2
Phase mix
PHASE28
How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.